Actinium Pharmaceuticals' Series E Round

Actinium Pharmaceuticals raised a round of funding on October 12, 2011. Investors include Laidlaw & Company.

Actinium Pharmaceuticals engages in the research, development, and commercialization of the alpha emitting isotopes bismuth 213 and actinium 225 for fighting cancer and other cellular diseases. The Co…

Articles about Actinium Pharmaceuticals' Series E Round: